About
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca Israel was established at the end of 2008 and is based in Kfar Saba, employing over 100 people, specializing in sales, marketing, medical & regulatory affairs. In addition, AstraZeneca Israel has a strong presence of scientific research and development with partnerships across the country. In May 2019 AstraZeneca signed a MOU (memorandum of understanding) with the Israeli innovation authority, committing to invest and support the Israeli healthcare ecosystem. AstraZeneca Israel is proud to be an active part of the AstraZeneca Health Innovation Hubs network alongside the US, China, Sweden, and France
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was AstraZeneca Israel established and what is its primary focus?
- AstraZeneca Israel was established at the end of 2008 in Kfar Saba, employing over 100 people. It specializes in sales, marketing, medical & regulatory affairs, and has a strong presence in scientific research and development through partnerships across the country.
- What significant agreement did AstraZeneca sign with the Israeli Innovation Authority?
- In May 2019, AstraZeneca signed a Memorandum of Understanding (MOU) with the Israeli Innovation Authority, committing to invest in and support the Israeli healthcare ecosystem.
- What is AstraZeneca's involvement in the Health Innovation Hubs network?
- AstraZeneca Israel is an active part of the AstraZeneca Health Innovation Hubs network, alongside hubs in the US, China, Sweden, and France.
- What was the nature of the deal between Compugen and AstraZeneca in December 2025?
- In December 2025, Compugen monetized a portion of its future royalties from Rilvegostomig to AstraZeneca for up to $90 million, converting potential future royalties into immediate cash.
- What was the outcome of AstraZeneca's Baxdrostat study in October 2025?
- In October 2025, AstraZeneca's Baxdrostat met its goal in a resistant hypertension study.
- What partnership did AstraZeneca form in China in June 2025?
- In June 2025, AstraZeneca formed an AI deal in China.
- What initiative did AstraZeneca launch in Tel Aviv in April 2025?
- In April 2025, AstraZeneca set up a Tel Aviv center to study Israeli health data, partnering with Tel Aviv University and the Meuhedet and Leumit health funds.
- What partnership did AstraZeneca establish with an Israeli AI startup in September 2024?
- In September 2024, AstraZeneca forged an $18 million partnership with an Israeli AI startup for cancer drug trials.
- What collaboration did AstraZeneca participate in for a computational science lab in Israel?
- In October 2021, AstraZeneca, along with Pfizer, helped launch a computational science lab in Israel.
- What joint initiative did JVP and AstraZeneca launch in February 2020?
- In February 2020, JVP and AstraZeneca launched a joint Digital-Health Initiative.